Dr. Michelle Mahler is a Pediatric Hematologist Oncologist with experience in all stages of clinical drug development and is the Chief Medical Officer of 1 E therapeutics.

Prior to joining 1E Therapeutics she was the VP of clinical research and development at C4Therapeutics, where she led the successful filing of INDs and initiation of their first in human oncology programs.

Prior to C4 Therapeutics Michelle spent almost 10 years at Janssen R&D. During her time there she had multiple roles across all stages of drug development with increasing responsibility.

Highlights include leading registration studies in ibrutinib, submissions to the FDA and EMA, leadership in pediatric development, global launch work for Imbruvica, and commercialization, strategy and reimbursement activities in global medical affairs. Other activities of note included work in BARDA funded program and due diligence activities, including clinical leadership in the acquisition of Momenta pharmaceuticals by JNJ.

Prior to starting in industry Dr. Mahler trained in Pediatric Hematology and Oncology at Memorial Sloan Kettering Cancer Center and New York Presbyterian Hospital/ Weill Cornell,and General Pediatrics at Mount Sinai Medical Center in NY. Michelle obtained her medical degree from University of the Witwatersrand, South Africa.